

***In vitro* blood-brain-barrier permeability and cytotoxicity of atorvastatin-loaded nanoformulation against glioblastoma in 2D and 3D models**

Michael M. Lübtow¹, Sabrina Oerter², Sabina Quader³, Elisabeth Jeanclos^{4,5}, Alevtina Cubukova⁶, Marion Krafft², Clemens Schulte¹, Laura Meier¹, Maximilian Rist¹, Oltea Sampetean⁷, Hiroaki Kinoh³, Antje Gohla⁴, Kazunori Kataoka^{3,8}, Antje Appelt-Menzel^{2,6}, Robert Luxenhofer^{1,9*}

¹ *Functional Polymer Materials, Chair for Advanced Materials Synthesis, Department of Chemistry and Pharmacy and Bavarian Polymer Institute, University of Würzburg, Röntgenring 11, 97070 Würzburg, Germany*

² *University Hospital Würzburg, Chair Tissue Engineering and Regenerative Medicine (TERM), Röntgenring 11, 97070 Würzburg, Germany*

³ *Innovation Center of Nanomedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-Ku, Kawasaki-Shi 210-0821, Japan*

⁴ *Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Straße 9, 97078 Würzburg, Germany*

⁵ *Rudolf Virchow Center for Experimental Biomedicine, University of Würzburg, Josef-Schneider-Straße 2, 97080 Würzburg, Germany*

⁶ *Fraunhofer Institute for Silicate Research ISC, Translational Center Regenerative Therapies TLC-RT, Röntgenring 11, 97070 Würzburg, Germany*

⁷ *Institute for Advanced Medical Research (IAMR), Division of Gene Regulation, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, 160-8582, Japan*

⁸ *Policy Alternatives Research Institute, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033 Japan*

⁹ *Soft Matter Chemistry, Department of Chemistry, Helsinki University, 00014 Helsinki, Finland*

correspondence to: robert.luxenhofer@uni-wuerzburg.de

Keywords

drug-loaded micelles, poly(2-oxazoline), poly(2-oxazine), nanomedicine, human induced-pluripotent stem cells, cancer stem cells

ABSTRACT: Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase of the family of statins have been suggested as therapeutic options in various tumors. Atorvastatin is a statin with potential to cross the blood-brain-barrier, however, the concentrations necessary for a cytotoxic effect against cancer cells exceeds the concentration achievable via oral administration, which made the development of a novel atorvastatin formulation necessary. We characterized the drug loading and basic physicochemical characteristics of micellar atorvastatin formulations and tested their cytotoxicity against a panel of different glioblastoma cell lines. In addition, activity against tumor spheroids formed from mouse glioma and mouse cancer stem cells, respectively, was evaluated. Our results show good activity of atorvastatin against all tested cell lines. Interestingly, in the 3D models, growth inhibition was more pronounced for the micellar formulation compared to free atorvastatin. Finally, atorvastatin penetration across a blood-brain-barrier model obtained from human induced-pluripotent stem cells was evaluated. Our results suggest that the presented micelles may enable much higher serum concentrations than possible by oral administration, however, if transport across the blood-brain-barrier is sufficient to reach therapeutic atorvastatin concentration for the treatment of glioblastoma via intravenous administration remains unclear.

1. INTRODUCTION

Glioblastoma (GBM) is the most common and most aggressive cancer of the central nervous system exhibiting dismal 5-year survival rates of 5 %.^[1, 2] Currently, surgical resection (limited due to diffuse and infiltrative nature of GBM) and concomitant chemoradiotherapy offer highest median survival rates of 14 months.^[3] Chemotherapy of GBM is especially challenging due to the rapid proliferative rate of GBM cells^[4], the appearance of treatment resistant cell clones shortly after initial treatment^[5, 6] as well as the limited access of systemically administered agents to the brain parenchyma due to the blood-brain-barrier (BBB)^[7, 8]. Despite these drawbacks, chemoradiotherapy greatly improves mean 3-year survival rates from 1.9 to 16 % compared to radiotherapy alone in the case of the most widely used chemotherapeutic agent for GBM treatment, temozolomide (TMZ).^[3] However, rapid development of TMZ resistance underline the urgent clinical need for better treatment options, potentially by using alternative active pharmaceutical ingredients (APIs) for GBM chemotherapy.^[9]

Statins are a family of widely used drugs for the treatment of hypercholesterolemia.^[10] They act as inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase thus being potent inhibitors of cholesterol biosynthesis.^[11] However, beyond their effects on serum cholesterol levels, recent research effort gives increasing evidence on cancer prevention and/or treatment properties of statins through interactions with essential cellular functions such as cell proliferation and differentiation.^[12] Several

in vitro and *in vivo* studies have demonstrated tumor growth inhibition as well as induction of apoptosis in various melanoma^[13], glioma^[14], neuroblastoma^[15], leukemia^[16] as well as glioblastoma cell lines^[17]. The underlying modes of action of statins causing (i) inhibition of tumor cell growth, (ii) repression of tumor metastases, (iii) inhibition of angiogenesis and (iv) induction of apoptosis were comprehensively reviewed by Hindler *et al.*^[12], Pisanti *et al.*^[18] and Gizzo *et al.*^[19]

As cell replication of GBM is highly dependent on the mevalonate (MVA) pathway for the synthesis of lipid moieties, their growth is naturally highly vulnerable to statins acting as competitive inhibitors of the enzyme regulating MVA synthesis – HMG-CoA reductase.^[20, 21] Furthermore, lovastatin increases the expression of the peroxisome proliferator-activated receptor, a transcription factor implicated in the control of lipid metabolism, cell growth and differentiation thus strongly reducing glioma proliferation.^[20] Real-time PCR analysis of U87 glioma spheroids revealed that atorvastatin (ATV) induced cell apoptosis by down-regulating the expression of anti-apoptotic Bcl-2 and up-regulating apoptotic caspase-3 and caspase-8 factors.^[22] Increase in caspase-3 activity in glioblastoma was also confirmed for other statins.^[17] Investigating the Ras downstream cascade, it was found that the increase was due to a reduced phosphorylation of extracellular signal-regulated kinase 1/2 (ERK1/2) and Akt. As the activation levels of these signal transduction molecules were restored in the presence of geranylgeranyl-pyrophosphate (GGPP), the inhibition of ERK1/2 and Akt activation in C6 glioma cells was correlated to the inhibition of GGPP biosynthesis.^[17] ATV also reduced the pro-tumorigenic effects of microglia on glioma migration and invasion by reducing the microglial expression of membrane type 1 metalloproteinase (MT1-MMP).^[23] It was suggested that the down-regulation of MT1-MMP was controlled by a p38 MAPK pathway in microglia. Furthermore, ATV was suggested to decrease the expression of pro-inflammatory proteins and interleukins (IL).^[24] This is important, as inflammatory microenvironment generally promotes malignant progression^[25] which is especially true for GBM^[26]. Although not discussed in direct correlation with GBM but worth mentioning, statins have been reported to sensitize cells to ferroptosis and induce ferroptosis in selected cell lines (however, further studies are necessary to confirm this).^[27] Furthermore, combination therapy of temozolomide and ATV in combination with radiotherapy in newly diagnosed GBM patients was promising (progression free survival (PFS) rate at 6 months: 67 % and median PFS of 9.1 months), meeting criteria for continued accrual in a phase II clinical study (NCT02029573).^[28] In addition, considerable evidence suggests that statins also exhibit immunomodulatory properties,^[18] as e.g. the number and suppressive function of regulatory T cells was decreased by ATV in patients with rheumatoid arthritis.^[29]

Although both, hydrophilic and lipophilic statins demonstrated antitumor effects, hydrophobic APIs generally exhibit a higher permeability through the BBB by e.g. passive diffusion.^[30] However, lipophilic substances also tend to be substrates for P-glycoprotein, potentially reversing this effect^[31, 32]. That this general trend is also true for statins was confirmed by Tsuji *et al.*^[33], observing permeation of lipophilic lovastatin and simvastatin but not of hydrophilic pravastatin through an artificial BBB *in vitro*, later this was also confirmed *in vivo*^[34]. Important to note, among various statins, ATV is the most frequently reported one for causing adverse neurocognitive effects compared to less lipophilic statins which was associated with its increased permeability through the BBB.^[35, 36]

Therefore, we chose lipophilic ATV as potential cytotoxic API against various glioblastoma cell lines.

However, besides the issue of passing the BBB, transportation of APIs to the BBB at sufficient high drug concentration is crucial. This can be especially challenging for hydrophobic APIs such as ATV which cannot simply be administered e.g. intravenously and oral bioavailability may not be sufficient to achieve concentrations necessary to reliably exhibit anti-tumor activity. Nanomedicine offers great potential regarding intravenous administration of water-insoluble drugs.^[37, 38] A few ATV-loaded polymer micelles based on amphiphilic polylactic acid-*b*-PEG-*b*-poly(lactic acid) (PLA-PEG-PLA) triblock copolymers^[39], PEG-poly(ϵ -caprolactone) (PEG-PCL) diblock copolymers^[40], PEG-*b*-vitamin E succinate (PEG-VES)^[41], stearyl grafted chitosan (SC)^[42] or ATV-loaded bovine serum albumin (BSA) nanoparticles^[43] can be found in the literature. However, to the best of our knowledge, none of these systems was investigated with respect to GBM treatment. Interestingly though, polysorbate 80 coated, ATV-loaded poly(lactic-*co*-glycolic acid)-*b*-PEG (PLGA-PEG) nanoparticles have been designed to investigate the influence of the coating on the transport of ATV to the brain.^[44] Important to note, both – coated and uncoated nanoparticles – were able to penetrate the BBB *in vivo* reaching maximum brain-concentration 1 h post-intravenous injection. Pioneering work by Kabanov and co-workers revealed that several amphiphilic polymers can facilitate transport of small molecules and proteins across the BBB.^[45-48]

2. MATERIALS AND METHODS

Reagents and Solvents

The monomers 2-*n*-propyl-2-oxazoline (PrOx), 2-*n*-propyl-2-oxazine (PrOzi), 2-*n*-butyl-2-oxazoline (BuOx) and 2-*n*-butyl-2-oxazine (BuOzi) were synthesized according to Seeliger *et al.*^[49] as reported recently^[50]. The polymers **A-pPrOx-A** (Me-MeOx₃₆-PrOx₂₀-MeOx₃₆-1-Boc-piperazine (PipBoc)), **A-pBuOx-A** (Me-MeOx₃₅-BuOx₂₀-MeOx₃₅-piperidine), **A-pPrOzi-A** (Me-MeOx₃₅-PrOzi₂₀-MeOx₃₅-PipBoc) and **A-pBuOzi-A** (Prop-MeOx₃₅-BuOzi₂₀-MeOx₃₅-PipBoc) were synthesized recently.^[50] Pluronic® was a mixture of Pluronic® F127 and L61 at 8/1 (w/w) corresponding to the ratio reported for SP1049C®. Atorvastatin (calcium salt trihydrate) was purchased from *Sigma-Aldrich* (HPLC \geq 98 %). Deuterated chloroform (CDCl₃), dimethyl sulfoxide (DMSO-*d*₆) or water (D₂O) for ¹H-NMR analysis were obtained from *Deutero GmbH* (Kastellaun, Germany).

Experiments

Nuclear Magnetic Resonance Spectroscopy (NMR)

NMR spectra were recorded on a Fourier 300 (300 MHz), *Bruker Biospin* (Rheinstetten, Germany) at 298 K. The spectra were calibrated to the signal of residual protonated solvent signal (CDCl₃: 7.26 ppm; DMSO-*d*₆: 2.50 ppm, D₂O: 4.79 ppm).

ATV-loaded Polymer Micelles

ATV-loaded polymer micelles were prepared by thin film method.^[51] Methanolic polymer (20 g/L) and ATV (20 g/L) stock solutions were mixed in desired ratio. After complete removal of the solvent at 40 °C under a mild stream of argon, the films were dried *in vacuo* (\leq 0.2 mbar) for 20 min. Subsequently, H₂O was added. Complete solubilization was facilitated by shaking the solutions at 1250 rpm at 35 °C for 12 min with a Thermomixer comfort, *Eppendorf AG* (Hamburg, Germany). Non-solubilized drug (if any) was removed by centrifugation for 5 min at 9.000 rpm with a

MIKRO 185 (Hettich, Tuttlingen, Germany). Solubilization experiments were performed with 3 individually prepared samples and results are presented as mean \pm standard deviation (SD).

ATV Quantification by HPLC

ATV quantification was performed by HPLC on a LC-20A Prominence HPLC, Shimadzu (Duisburg, Germany) equipped with a system controller CBM-20A, a solvent delivery unit LC-20 AT (double plunger), an on-line degassing unit DGU-20A, an auto-sampler SIL-20AC, and a SPD-20A UV-Vis detector. As stationary phase, a ZORBAX Eclipse Plus, Agilent (Santa Clara, CA, USA) C18 column (4.6 x 100 mm; 3.5 μ m) was used. The mobile phase was a gradient of H₂O/ACN (60 % - 40 % H₂O; Figure S1a) at 40 °C and a flow rate of 1 mL/min. Prior to ATV quantification, all formulations were centrifuged to remove any precipitate, diluted with ACN/H₂O = 60/40 (v/v) and quantified at 245 nm (Figure S1b). The following equations were used to calculate loading capacity (LC) and loading efficiency (LE):

$$LC = \frac{m_{drug}}{m_{drug} + m_{polymer}} \quad (1)$$

$$LE = \frac{m_{drug}}{m_{drug,added}} \quad (2)$$

where m_{drug} and $m_{polymer}$ are the weight amounts of solubilized drug and polymer excipient in solution and $m_{drug,added}$ is the weight amount of drug initially added to the dispersion. No loss of polymer during micelle preparation was assumed.

Long-term Stability Studies

For long-term stability studies, ATV-loaded polymer micelles were stored in Eppendorf tubes containing the precipitate (if any occurred) at ambient conditions (\approx 25 °C) under the exclusion of light. Prior to ATV quantification, all formulations were centrifuged to remove any precipitate, diluted with ACN/H₂O = 60/40 (v/v) and quantified by HPLC analysis at 245 nm.

Dynamic Light Scattering (DLS)

DLS measurements were performed on a Zetasizer Nano ZS (Malvern Panalytical GmbH, Kassel, Germany) with a 633 nm HeNe-laser at 173°. Autocorrelations for each sample were obtained 3 times for 40 seconds and results are presented as mean. Prior to the measurements, all samples (polymer = 10 g/L) were diluted 1/5 (v/v) with ultrapure H₂O to polymer = 2 g/L. The samples were measured unfiltered in quartz cuvettes (d = 10 mm, QS, Hellma) at 25 °C.

2D Cell Viability and Migration Studies

Mouse glioma cells (CT-2A and GL261) as well as human glioblastoma cells U373, U251 and U87 were cultured in Dulbecco's Modified Eagle's medium (DMEM; Sigma-Aldrich, St. Louis, USA) (high glucose) supplemented with 10 % fetal bovine serum (FBS). In the case of CT-2A, U373 and GL261, 1 % penicillin/streptomycin (P/S) was added. For U373, Gibco® MEM non-essential amino acids were added as well. For the determination of IC₅₀, cells were seeded at 3×10^3 cells/well in transparent flat-bottom 96 well-plates and cultured for 1 d in humidified atmosphere of 5 % CO₂ at 37 °C. DMSO/ATV was prepared by dissolving 10 g/L ATV in DMSO and diluted with D-PBS(-) (PBS = phosphate buffered saline, FUJIFILM Wako Pure Chemicals Corporation (Osaka, Japan) to 1 g/L ATV before further dilution with cell specific medium to desired ATV concentrations. ATV-loaded **A-pBuOzi-A** micelles were prepared by thin-film method ($\rho(\mathbf{A-pBuOzi-A}/\text{ATV}) = 10/1$ [g/L])

and diluted with cell-specific medium to desired ATV concentrations. The respective solutions were applied for 24 h, 48 h and 72 h. After treatment, Cell Counting Kit-8 (CCK8) cell proliferation/cytotoxicity assay was performed according to manufacturer's instructions. Briefly, 10 μ L of CCK-8 solution were added per well and the samples incubated for 2 h at 37 °C and 5 % CO₂. Absorption was measured at $\lambda_{abs} = 450$ nm with an Infinite 200 (Tecan, Männedorf, Switzerland).

Cell viability was determined by equation 3:

$$cell\ viability = \frac{F_{treated} - F_{medium}}{F_{untreated} - F_{medium}} \times 100\% \quad (4)$$

where $F_{treated}$ and $F_{untreated}$ correspond to the absorption of treated and untreated cells, respectively, and F_{medium} is the absorption of the culture medium.

Cell viability experiments were performed with three individual 96 well-plates containing each sample concentration in quadruplicate and results are presented as means \pm SD. IC₅₀ was determined with OriginPro 2019 software using a Boltzmann or biphasic dose-response fit.

Human pediatric cerebellar glioblastoma multiforme GBM6840 cells were cultured in DMEM (high glucose) supplemented with 10 % FBS. Cell viability studies and IC₅₀ determinations were conducted by live/dead cell staining and flow cytometric analysis. Briefly, cells were seeded in 96 well-plates (10⁴ cells/well). The next day, ATV (solubilized in DMSO or formulated with **A-pBuOzi-A**) was added to the medium at a final concentration of 0 to 80 μ M. The corresponding concentrations of DMSO and **A-pBuOzi-A** alone served as controls. After 48 h incubation, cells were rinsed with PBS, trypsinized, and resuspended in 250 μ L PBS containing 0.5 g/L soybean trypsin inhibitor (*Invitrogen*, Carlsbad, USA). Cell culture medium, wash solution and trypsinized cells were collected and incubated for 15 min at 22 °C with the live cell indicator calcein-AM (*Invitrogen*, Carlsbad, USA) at a final concentration of 10 nM. Immediately before flow cytometry, cell suspensions were incubated with the dead cell indicator propidium iodide (1 mg/L, *Invitrogen*) for 1 min. Cells were analyzed on a FACS Calibur flow cytometer (*Beckton Dickinson*, Heidelberg, Germany); at least 5,000 cells were analyzed per condition. Data are presented as means \pm SEM of $n=3$ independent experiments. Cell viability was expressed as the percentage of calcein-positive cells. IC₅₀ values were determined by non-linear regression (log(inhibitor) vs. response – variable slope (four parameters)) using Prism v7.04 (*GraphPad*, San Diego, U.S.A.).

For cell migration studies, 2×10^5 GBM6840 cells were seeded in 3 cm dishes and treated with 0, 2.5 or 5 μ M ATV formulated with **A-pBuOzi-A** for 65 h. GBM6840 cells were trypsinized, resuspended in 1 mL DMEM containing 0.5 mg/mL soybean trypsin inhibitor, and washed once by centrifugation (300 \times g, 5 min at RT). The cell suspension (2.5×10^4 cells/0.5 mL DMEM) was added to the upper compartment of a transwell (Falcon cell culture inserts for 24 well-plates, 8 μ m pore size; *ThermoFisher Scientific*). The bottom side of the membrane was pre-coated with fibronectin (10 mg/mL; *Sigma-Aldrich*) to assure attachment of the transmigrated cells; epidermal growth factor (100 ng/mL; *Sigma-Aldrich*) was used as a chemoattractant in the lower transwell compartment. Cells were allowed to migrate for 8 h in a humidified tissue culture incubator (37 °C, 5 % CO₂) in the presence of 0, 2.5 or 5 μ M ATV. Remaining cells on the upper side of the transwell membranes were removed with cotton swabs, and cells on the lower side of

the membranes were fixed with 4 % (w/v) para-formaldehyde for 20 min. Nuclei were stained with 4',6-diamidino-2'-phenylindole (DAPI, 1 µg/mL) in PBS, and transwells were mounted on coverslips using Immunomount (*ThermoFisher Scientific*). Cell nuclei were visualized on a Leica SP5 confocal microscope (*Leica Microsystems*) equipped with a 10× objective, and four images covering ≈ 75 % of the total transwell membrane surface area were taken for each transwell. Cell numbers were quantified semi-automatically using ImagePro-Plus software, version 7.0 (*Media Cybernetics*, Rockville, U.S.A.).

3D Spheroid studies

CT-2A cells were cultured in DMEM supplemented with 10 % FBS and 1 % P/S. Mouse brain tumor initiating bRiTS-G2 cells were cultured in DMEM/F12 (*Wako*, Osaka, Japan) supplemented with 20 ng/mL epidermal growth factor, 20 ng/mL basic fibroblast growth factor (both *PeprTech*, Rocky Hill, NJ), B27 supplement without vitamin A (*Invitrogen*, Carlsbad, USA) and 200 ng/mL heparan sulfate (*Sigma-Aldrich*, St. Louis, USA). For spheroid studies, cells were seeded at 5×10^3 cells/well in all white U-bottom 96 well-plates (*PrimeSurface96U*, *Sumitomo Bakelite Co.* Tokyo, Japan) and incubated for 1 d in humidified atmosphere of 5 % CO₂ at 37 °C. Within this time, 3D cell aggregates of around 400 µm diameter were spontaneously formed (Figure S2). Subsequently, stock solutions of **A-pBuOzi-A**/ATV ($\rho(\text{A-pBuOzi-A}/\text{ATV}) = 10/1$ [g/L] in ultrapure H₂O) or DMSO/ATV (ATV = 10 g/L) were diluted with cell specific culture medium to desired concentrations and applied for 48 h and 72 h. After treatment, CellTiter-Glo® 3D Luminescent Cell Viability Assay (*Promega*, Madison, USA) was performed according to manufacturer's instructions. Briefly, 100 µL of CellTiterGlo® 3D solution were added per well (100 µL) and stored for 30 min at ambient conditions (≈ 25 °C) under the exclusion of light. Luminescence was measured with a GloMax®-Multi+ Detection System (*Promega*, Madison, USA). Spheroid studies were performed with three individual 96 well-plates containing each sample concentration in quadruplicate and results are presented as means ± SD.

2D human iPSC-BBB Studies

Human induced-pluripotent stem cells (hiPSC; IMR90-4, *WiCell Research Institute*, USA) were cultured in mTeSR™1 medium (*Stem-Cell Technologies*, Canada). The iPSC-derived BBB model was built as previously described.^[52] Cytotoxicity of **A-pBuOzi-A**/ATV or DMSO/ATV against hiPSC-derived endothelial cells (hiPS-ECs) was evaluated for three concentrations (45 µM, 90 µM and 150 µM) after 4 h and 24 h incubation. After treatment, CellTiter-Glo® 3D Luminescent Cell Viability Assay (*Promega*, Mannheim, Germany) was performed according to manufacturer's instructions. Luminescence was measured with an Infinite M200 fluorescence reader (*Tecan Group*, Switzerland). Cytotoxicity studies were performed in triplicates and three independent biological replicates and results are presented as means ± SEM.

To evaluate human BBB-like characteristic, transendothelial electrical resistances (TEER) were determined with a Millicell ERS-2 voltohmmeter (*Millipore*, USA) equipped with a STX3 electrode (*World Precision Instruments*, Germany) prior transport assay. TEER measurements were performed 40 min after medium change. Each model was measured three times, monitoring and excluding a possible data drift due to temperature fluctuations and duplicates were used for each experiment in three independent biological replicates. To yield the TEER values [$\Omega \cdot \text{cm}^2$] resulted

from BBB hiPS-ECs, average TEER of empty inserts coated with collagen IV/fibronectin were subtracted and values were multiplied by insert surface. Results are presented as means ± SEM.

Permeation through BBB endothelium

Transport assays were performed in transwells (24-well format) on an orbital shaker (*Edmund Bühler GmbH*, Germany) at 100 rpm, 37 °C, 95 % humidity, and 5 % CO₂. Stock solutions of **A-pBuOzi-A**/ATV or DMSO/ATV were diluted with human endothelial-SFM (*Thermo Fisher Scientific*, USA) containing 1 % platelet poor-plasma derived serum (PPPDS; *Alfa Aesar*, USA) to the desired concentrations ([ATV] = 90 µM and 150 µM). Test concentrations of **A-pBuOzi-A**/ATV or DMSO/ATV (200 µL) were applied to the apical side of the BBB model. The basolateral side was supplied with 800 µL of human endothelial-SFM containing 1 % PPPDS and the respective concentration of sterile water (**A-pBuOzi-A**) or DMSO. The permeation was evaluated after incubation times of 4 h and 24 h. Apical and basolateral media were analyzed by HPLC to quantify the transport of **A-pBuOzi-A**/ATV or DMSO/ATV. As control, the substances were incubated on empty collagen IV/fibronectin-coated inserts to exclude major ATV adsorption on the membrane. All permeability studies were performed in duplicates and three independent biological replicates, results are presented as means ± SD. The level of statistical significance was set at $p < 0.05$, indicated with asterisk (*). Grading in significance is indicated as follows: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.

3. RESULTS AND DISCUSSION

ATV solubilization

As reported recently, poly(2-oxazoline) (POx) and poly(2-oxazine) (POzi) based ABA triblock copolymers, all comprising the same hydrophilic poly(2-methyl-2-oxazoline) (PMeOx) shell **A** and structurally very similar, hydrophobic cores **B** exhibit different loading capacities for various hydrophobic drugs^[50, 53-57] as well as varying drug/polymer interactions in dependence of the drug-loading^[58, 59]. Whereas the triblock copolymer with a barely hydrophobic poly(2-*n*-butyl-2-oxazoline) (pBuOx, = **A-pBuOx-A**) core enabled moderately high loadings of 24 wt.% of the hydrophobic compound curcumin (CUR), its structural isomer with a poly(2-*n*-propyl-2-oxazine) (pPrOzi; = **A-pPrOzi-A**) core was able to yield exceptionally high loadings up to 54 wt.%.^[53] Interestingly, in the case of hydrophobic paclitaxel (PTX), the situation was *vice versa*, **A-pBuOx-A** being the best performer with PTX loadings up to 48 wt.% compared to 25 wt.% in the case of **A-pPrOzi-A**. As the drug loading is a crucial parameter concerning the translation of drug-loaded polymer micelles into the clinics, we investigated both polymers with regard to their solubilization capacity for the non-water soluble drug atorvastatin (ATV; water solubility of ATV calcium salt trihydrate by thin film-method = 60 mg/L (0.1 mM); analyzed in house). Additionally, two polymers comprising either a poly(2-*n*-propyl-2-oxazoline) (pPrOx; = **A-pPrOx-A**) or poly(2-*n*-butyl-2-oxazine) (pBuOzi; = **A-pBuOzi-A**) core were investigated for solubilization. The mixture of two Pluronics® SP1049C, which was developed by Kabanov for the interference with P-glycoprotein (P-gp) and therefore, improved delivery of hydrophobic molecules across biological barriers such as the BBB overexpressing P-gp^[60-62] was included for comparison (Figure 1a). As expected, distinct polymer-ATV solubilization specificities were observed for the formulations prepared by thin film method (Figure 1b). Whereas **A-pPrOx-A** enabled ATV concentrations of only 0.7 g/L ($LC = 6.4$

wt.%; ATV-feed = 10 g/L), its POzi counterpart with the same propyl-side chain **A-pPrOzi-A** solubilized up to 4.2 g/L ATV ($LC = 29$ wt.%; ATV feed = 10 g/L), being outperformed only by **A-pBuOzi-A** with up to 6.9 g/L ATV ($LC = 41$ wt.%; ATV feed = 10 g/L) (Figure 1c). Again, the POx with the same side chain **A-pBuOx-A** exhibited lower LC s of up to 25 wt.% (3.3 g/L; ATV feed = 10 g/L). The LC of Pluronic® was 6 times lower with ATV = 0.7 g/L ($LC = 6.4$ wt.% ATV-feed = 10 g/L), showing the same LC as **A-pPrOx-A**. As **A-pBuOzi-A** also exhibited the best long-term stability showing only minor loss in ATV-content up to ATV feed concentrations of 5 g/L within 30 d storage (Figure 1d; for 30 d long-term stability of all other formulations, please see Figure S3) this carrier was deemed most promising for further studies. Therefore, the physicochemical properties of **A-pBuOzi-A/ATV** formulations were investigated in more detail.




Figure 1: a) ABA triblock-copolymers used for ATV solubilization by b) thin-film method; c) solubilized aqueous ATV concentrations in dependence of the ATV feed by **A-pPrOx-A**, **A-pPrOzi-A**, **A-pBuOx-A**, **A-pBuOzi-A** or Pluronic® F127/L61 8/1 (w/w) at polymer = 10 g/L.; d) Long-term stability of **A-pBuOzi-A/ATV** formulations. Formulations were stored in Eppendorf-tubes containing the initial precipitate at ambient conditions ($T \approx 25$ °C) under the exclusion of light. All formulations were prepared in triplicates and results are presented as means \pm SD; e) particle size distribution determined by dynamic light scattering of **A-pBuOzi-A/ATV** formulations in dependence of the solubilized ATV concentration at room temperature (≈ 25 °C) at 173° with a Zetasizer Nano ZS. The samples (**A-pBuOzi-A** = 10 g/L) were diluted with H₂O 1/5 (v/v) and measured unfiltered; f) mean hydrodynamic diameter D_h (intensity weighted) of the ATV-loaded **A-pBuOzi-A** micelles. Each formulation was prepared three times and data is given as mean \pm SD ($n = 3$). Inset in figure f) shows visual appearance of undiluted **A-pBuOzi-A/ATV** = 10/0.5; 10/0.8 and 10/2.8 g/L formulations.

Particle sizes of the **A-pBuOzi-A/ATV** formulations were highly dependent on the ATV-loading. At rather low loadings of 0.5 and 0.9 g/L (polymer = 10 g/L), micelles with average hydrodynamic diameters D_h of 15 nm and 26 nm were found, respectively (Figure 1e). The size distributions were monomodal with corresponding PDIs of 0.22 (Figure 1f). Increasing the ATV-loading to 2.8 and 4.0 g/L resulted in a dramatic increase in particle size to 609 nm and 847

nm, respectively, accompanied by an increase in PDI to 0.31 – 0.32. The increase in size was also apparent by visual inspection of the formulations (inset Figure 1f). Whereas up to **A-pBuOzi-A/ATV** = 10/0.8 g/L the formulations were completely clear, the sample containing 2.8 g/L ATV was opaque and emulsion-like (however samples for DLS were diluted 1/5 (v/v) to suppress artefacts due to multiple scattering etc.). Although being opaque, the samples did not show precipitation over extended periods of time (determined by visual inspection as well as relatively constant ATV loading up to 30 d (ATV feed = 5 & 8 g/L) or 10 d (ATV feed = 10 g/L) storage (Figure 1d)). A more detailed analysis of these aggregates using, *inter alia*, small angle neutron scattering is ongoing. However, such large aggregates, irrespective of their nature or structure are probably not ideal for the envisioned application *i.v.* for which smaller and better-defined micelles are preferred.

To get more insights into the ATV formulations on a molecular level^[59], ¹H-NMR spectra of neat ATV, neat polymer or ATV formulations at varying **A-pBuOzi-A/ATV** ratio were recorded. In DMSO-*d*₆, all signals related to ATV were clearly visible with expected intensities (Figure 2; black spectrum; for enlarged ATV and **A-pBuOzi-A** spectra, the reader is referred to Figure S4 and S5, respectively). In contrast, when solubilized with **A-pBuOzi-A**, ¹H-NMR signals of ATV were either strongly attenuated and broadened (**A-pBuOzi-A/ATV** $\leq 10/0.9$) or could not be detected anymore (**A-pBuOzi-A/ATV** $> 10/0.9$) in D₂O (Figure 2; enlarged spectra). A similar disappearance of ¹H-NMR signals was already observed for **A-pPrOzi-A/CUR** formulations.^[63] Systems which are hindered in their mobility are predestinated for short transverse relaxation times T_2 causing a broadening or complete disappearance of certain signals. Therefore, the disappearance of the ¹H-NMR signals indicates a strong decrease in molecular mobility of ATV incorporated into the hydrophobic core of **A-pBuOzi-A** even at low loading. Furthermore, the signals of the butyl sidechain of the hydrophobic block are clearly affected (Figure 2 III-V). Notably, the signal attributed to the methyl group in the sidechain of pBuOzi (signal V) splits up. Besides the initial triplet, a second, much broader signal was observed at lower chemical shift. Similarly, but somewhat less pronounced, signals III and IV shift and became increasingly attenuated with increasing ATV loading. This decrease again is intuitive for a hindered mobility due to interactions of ATV with the hydrophobic block of **A-pBuOzi-A**. In contrast, the signals related to the hydrophilic shell (Figure 2 I,II) appear entirely unaffected even at the highest investigated drug loading. This results in a decreased ratio of the integrals of the methyl group of pBuOzi (core, signal V) with respect to the methyl sidechain of pMeOx (shell, signal II) with increasing ATV-loading (Figure S6). The more or less linear decrease of the ratio as well as the largely unaffected signals related to the hydrophilic shell are somehow surprising considering the large change in particle size at higher ATV-loadings observed by DLS (Figure 1e,f). Also, we previously investigated **A-pPrOzi-A/CUR** formulations by solution and solid state NMR^[59] and found clear evidence for drug-polymer interactions in the hydrophilic pMeOx block. The lack of interaction of ATV with the pMeOx may therefore be responsible for the limited LC compared to CUR^[63] or PTX^[51] nanoformulations which exhibit LC of ≥ 50 wt.%. For reference, interactions between encapsulated ATV and the hydrophobic part of the polymeric drug carrier were observed previously for PLA-PEG-PLA-loaded ATV by FT-IR analysis.^[39]




Figure 2: $^1\text{H-NMR}$ spectra (300 MHz, 298 K) of ATV (bottom black spectrum; DMSO-d_6), neat **A-pBuOzi-A** (middle red spectrum; D_2O) as well as **A-pBuOzi-A/ATV** = 10/0.5 g/L (top golden spectrum; D_2O). Inset shows enlarged region corresponding to aromatic ATV signals (700-fold increased signal intensity) with increasing ATV-loading (bottom to top; labelling is referred to **A-pBuOzi-A/ATV** = 10/ y g/L). Enlarged sections of the signals corresponding to the hydrophilic shell of **A-pBuOzi-A** (I & II) as well as the hydrophobic core (III – V) in dependence of the ATV-loading. Intensities of spectra I-V were normalized to the methyl sidechain (II) of the hydrophilic shell. All formulations were prepared in H_2O , freeze-dried and subsequently redissolved in D_2O at $\rho(\text{polymer}) = 10$ g/L.

Although stability of the aqueous **A-pBuOzi-A/ATV** formulations up to ATV feeds of 8 g/L was reasonably good, a minor loss in ATV content occurred in all formulations within 30 d storage (Figure 1d). Shelf-life of drug-loaded micelles can potentially be increased by freeze-drying the aqueous formulations and redispersing them right before usage. POx and POzi based formulations of PTX^[51] or CUR^[63] have already displayed excellent redispersibility without the need of cryoprotectants. Similar, freeze-dried **A-pBuOzi-A/ATV** = 10/2 g/L formulations could be conveniently redispersed in H_2O (Figure 3 blue), PBS (red) or PBS containing 40 g/L bovine serum albumin (BSA, green) after 7 d storage of the freeze-dried formulations at ambient conditions. Redispersion in PBS containing 40 g/L BSA corresponding to the albumin concentration in blood was performed as preliminary test for upcoming *in vitro* and potential *in vivo* studies, as initially stable formulations can precipitate in the presence of proteins. The excellent stability in the presence of serum protein suggests that this formulation may be safely injected *i.v.*




Figure 3: Residual aqueous ATV concentrations after redispersion of freeze-dried **A-pBuOzi-A/ATV** = 10/2 (g/L) formulations in H_2O (blue), PBS (red) or PBS containing 40 g/L bovine serum albumin (green). Loading [%] is referred to initial ATV concentration before freeze-drying. Prior to redispersion, the freeze-dried samples were stored for 7 d at ambient conditions ($T \approx 25^\circ\text{C}$) under the exclusion of light; b) corresponding HPLC elugrams at $\lambda_{\text{abs}} = 245$ nm.

2D *in vitro* studies

Cytotoxicity of **A-pBuOzi-A/ATV** or ATV dissolved in DMSO against mouse glioma cells GL261 and CT-2A or human glioblastoma cells U87, U251 and U373 was evaluated after 24 h, 48 h and 72 h incubation (Figure 4). To the best of our knowledge, a potential growth inhibition or cytotoxicity of ATV against GL261, CT-2A and U373 has not previously been investigated. Except for CT-2A, cytotoxicity after 24 h incubation was moderate with half maximal inhibitory concentrations (IC_{50}) of 97 μM and higher. A similar low cytotoxicity of ATV after 24 h incubation (no decrease in proliferation up to $[\text{ATV}] = 50 \mu\text{M}$) compared to 48 h and 72 h was observed for human leukemic natural killer cells YT-INDY.^[64] Furthermore, absence of cytotoxicity against U87 after 24 h incubation at $[\text{ATV}] \leq 100 \mu\text{M}$ was also observed by Yongjun *et al.*^[23] In contrast, ATV exhibits a pronounced dose-dependent cytotoxicity after 48 h and 72 h incubation. The IC_{50} values for **A-pBuOzi-A/ATV** and DMSO/ATV were either comparable (U87 (72 h); U373 (48 and 72 h)) or slightly lower for **A-pBuOzi-A/ATV**. Generally, cytotoxicity increased from 48 h to 72 h incubation. Only for CT-2A, an unexpected increase in cell viability with IC_{50} values increasing from 33 μM (48 h) to 98 μM (72 h) occurred for DMSO/ATV . Furthermore, biphasic dose-response curves occurred in selected cases for DMSO/ATV (GL261) as well as **A-pBuOzi-A/ATV** (U251). Such multiphasic features are well known in cancer pharmacology^[65] due to the presence of combined agonist (stimulatory or hormetic^[66]) and antagonist effects as well as purely inhibitory features. Nevertheless, that with the same drug (ATV) both, sigmoidal and biphasic dose-responses occurred for a certain cell-line depending on the kind of formulation (DMSO or **A-pBuOzi-A**) is somehow surprising and needs to be evaluated further. Important to note, IC_{50} of DMSO/ATV for U87 ($\approx 8 \mu\text{M}$ (48 h)^[67] or $\approx 1.6 \mu\text{M}$ (48 h)^[68]) or U251 ($\approx 10 \mu\text{M}$; 48 h^[67]) cells reported in the literature were somewhat lower than the presently reported ones. However, different experimental setups (# cell passage, number of cells seeded, utilized assays) might have unintentionally caused such minor deviations. Important to note, inhibitory effects of ATV on growth and survival of U251 glioblastoma cells were attributed to decreased active Ras levels due to prenylation inhibition by ATV.^[67] In the same study, 5 μM ATV inhibited proliferation of four different glioblastoma cell lines slightly stronger than temozolomide at 10 μM . In combination with the presented cytotoxicity of ATV on various glioblastoma cell lines this strongly supports the rationale to use ATV for glioblastoma chemotherapy. The dismal prognosis of glioblastomas is not only attributed to rapid tumor growth (and poor responses to chemo- and radiotherapy), but also to the diffuse intracerebral spread of migrating tumor cells.^[69, 70] We therefore examined the effects of ATV on the viability and cell migration of GBM6840 cells. This human cell line has been derived from a highly aggressive pediatric cerebellar glioblastoma multiforme^[71], and is characterized by rapid cell proliferation and –migration *in vitro* and *in vivo*^[72]. The GBM6840 cells were highly sensitive to ATV with an IC_{50} value of $\sim 8 \mu\text{M}$ after 48 h treatment, irrespective of whether ATV was dissolved in DMSO or formulated with **A-pBuOzi-A** (Figure 5a; for representative examples of the original FACS results, the reader is referred to Figure S7). Importantly, neat **A-pBuOzi-A** did not cause cytotoxicity (viability > 80 %) up to high polymer concentrations of 10 g/L (Figure S8; for comparison: **[A-pBuOzi-A]** = 50 mg/L @ $\text{IC}_{50}(\text{A-pBuOzi-A/ATV})$, Figure 5a). We did not observe an effect of low ATV concentrations (2.5 or 5 μM) on the transwell-migration of GBM6840 cells towards epidermal growth factor (a prototypical chemoattractant for glioblastoma cells) even after 73 h of ATV treatment (Figure 5b). These ATV

concentrations were chosen because they did not cause a substantial loss of cell viability (Figure S9). Thus, ATV appears to primarily affect GBM6840 cell viability, but not mobility.




Figure 4: Concentration-dependent cell viability of **A-pBuOzi-A/ATV** (left column) or **DMSO/ATV** (right column) against mouse glioma cells **GL261** (a,b) and **CT-2A** (c,d), or human glioblastoma cells **U87** (e,f), **U251** (g,h) and **U373** (i,j). **DMSO/ATV** was prepared by dissolving 10 g/L (18 mM) **ATV** in **DMSO** upon dilution with **PBS(-)** to 1 g/L (1.8 mM) **ATV** and further dilution with cell specific medium to desired **ATV** concentrations. **ATV-loaded A-pBuOzi-A** micelles were prepared by thin-film method ($\rho(\text{A-pBuOzi-A/ATV}) = 10/1$ [g/L]) and diluted with cell-specific medium to desired **ATV** concentrations. Cell viability was determined (CCK-8 assay) after 24 h (black), 48 h (red) and 72 h (blue) **ATV** treatment. IC_{50} was determined per Boltzmann or biphasic dose-response fit using OriginPro 2019® and values for 24 h (black), 48 h (red) and 72 h (blue) are given in μM **ATV** in bottom left corner of each graph. Data are presented as mean \pm SD ($n = 3$ (individual 96 well-plates) \times 4 (wells per 96 plate)).

Spheroid cell cultures

So far, we could show that **ATV** was able to efficiently decrease cell-viability of various glioblastoma cell-lines in conventional 2D cell culture. However, cancer cells grown in 3D cell-clusters such as spheroids can behave significantly different from their monolayer counterparts^[73] and we have recently reported differences in tumor spheroids depending whether the API was administered in polymer micelles or added as a ethanolic solution.^[57] The multi-

cellular structures resemble actual tissues better in terms of structural and functional properties and often exhibit an enhanced resistance against therapeutic compounds.^[74] **CT-2A** cells were chosen due to their ability to form spheroids without the need of specialized devices or additives. Furthermore, the difference in cytotoxicity between **A-pBuOzi-A** (Figure 4c) and **DMSO** (Figure 4d) formulated **ATV** was most pronounced in this cell line. Spheroids were obtained by simply seeding the cells (5×10^3 cells/well) in U-bottom shaped 96 well-plates. Similar to conventional 2D-cell culture, both **ATV** formulations strongly decreased **CT-2A** cell viability in a concentration-dependent manner (Figure 6a,b). Here, **A-pBuOzi-A/ATV** again was clearly more effective than **DMSO/ATV**. Similar to conventional 2D cell culture (Figure 4d), cell viability in the spheroid model increased from 48 h (50 %) to 72 h (55 %) treatment with 8 μM **DMSO/ATV**. Unexpectedly, cytotoxicity of **A-pBuOzi-A/ATV** was higher in the spheroid model (Figure 6a,b) than in conventional 2D cell-culture (Figure 4c). A similarly high activity of **ATV** in 3D cell-culture was also observed for **U87** glioma spheroids incorporated into a fibrin gel with IC_{50} (48 h) $\approx 10 \mu\text{M}$.^[73] Besides induction of apoptosis, migration and invasion of the **U87** cells were inhibited in a dose-dependent manner in this case.




Figure 5: a) Concentration-dependent effect of **A-pBuOzi-A/ATV** (red) or **DMSO/ATV** (blue) on **GBM6840** human glioblastoma cell viability after 48 h treatment. **ATV** was formulated or solubilized as described in the legend of Fig. 4. IC_{50} values were determined by non-linear regression (log(inhibitor) vs. response – variable slope (four parameters)) using GraphPad Prism v7.04. Data are means \pm SEM of $n=3$ independent experiments. b) Effect of **A-pBuOzi-A/ATV** on the epidermal growth factor-induced migration of **GBM6840** cells through transwells. In total, eight (control and 2.5 μM **ATV**) or four (5 μM **ATV**) transwells were analyzed. Data are means \pm SEM of $n=2$ independent experiments.

To further challenge **ATV** as potential chemotherapeutic agent against glioblastoma, its activity against spheroids composed of mouse-derived, glioblastoma cancer-stem cells (CSCs) was evaluated (Figure 6c,d). CSCs are cancer cells found within tumors with the ability of self-renewal, generation of daughter cells of various phenotypes and differentiation into phenotypically diverse populations of cells.^[75] Therefore, small populations of CSCs present after treatment can cause rapid cancer relapse as well as metastasis. Unfortunately this is favored by an increased resistance of CSCs to various otherwise unfavorable conditions^[76] including increased resistance against radiotherapy^[77] and chemotherapy^[78]. To the best of our knowledge, the cytotoxicity of **ATV** against glioblastoma stem cells or cancer stem cells in general has not been investigated before. However, for another statin, pitavastatin, autophagy induction in patient-derived stem cell-like primary **GBM** (as well as delayed **U87** **GBM** tumor growth *in vivo*) was observed.^[21] Similar to **CT-2A**, the **bRiTS-G2** brain tumor initiating

cells rapidly formed spheroids when placed in U-bottom shaped 96 wells. Surprisingly, **A-pBuOzi-A/ATV** and to a lesser extent DMSO/ATV were highly active against the tumor spheres after 48 h and 72 h incubation (Figure 6c,d). Interestingly, a recently reported micellar mitotane nanoformulation of **A-pBuOx-A** was also slightly more active than mitotane simply dissolved in EtOH against adrenocortical NCI-H295R cells in a 3D tumor spheroid model ($IC_{50,48h} = 43 \mu\text{M}$ & $47 \mu\text{M}$ for nanoformulated & EtOH-dissolved mitotane, respectively).^[57] Important to note, the pronounced cytotoxicity of **A-pBuOzi-A/ATV** after 72 h treatment determined by CellTiterGlo®-3D luminescence assay was confirmed when quantifying the cell-viability by the intrinsic fluorescence of the GFP expressing bRITS-G2 cells (inset Figure 6d). Although the absolute values slightly differed, both measurement techniques gave comparable results.




Figure 6: Concentration-dependent cytotoxicity of **A-pBuOzi-A/ATV** (blue) or DMSO/ATV (yellow) against spheroids of mouse glioma cells CT-2A after a) 48 h or b) 72 h treatment or against spheroids of mouse brain tumor initiating bRITS-G2 cells after c) 48 h or d) 72 h treatment. DMSO/ATV was prepared by dissolving 10 g/L ATV in DMSO upon dilution with PBS(-) to 1 g/L ATV and further dilution with cell specific medium to desired ATV concentrations. ATV-loaded **A-pBuOzi-A** micelles were prepared by thin-film method ($\rho(\text{A-pBuOzi-A/ATV}) = 10/1$ [g/L]) and diluted with cell-specific medium to desired ATV concentrations. Spheroids were obtained by seeding the cells in U-bottom shaped 96 well-plates at 5×10^3 cells/well. Cell viability was determined by CellTiter-Glo® 3D assay. Data are presented as mean \pm SD ($n = 3$ (individual 96 well-plates) $\times 4$ (wells per 96 plate)). As a control, cell viability of bRITS-G2 spheroids treated with **A-pBuOzi-A** formulated ATV was determined by intrinsic fluorescence of GFP-expressing bRITS-G2 cells (inset Figure d). Data are presented as mean \pm SD ($n = 2$ (individual 96 well-plates) $\times 4$ (wells per 96 plate)).

ATV permeability through artificial blood-brain barrier

The pronounced cytotoxicity of ATV against glioblastoma in 2D cell culture (Figure 4, 5) as well as 3D spheroid models (Figure 6) suggests its potential for GBM chemotherapy. However, in order to unfold its therapeutic potential *in vivo*, ATV needs to reach tumor site first. This includes permeation through the BBB after e.g. parenteral administration.^[79] Several sophisticated *in vitro* BBB models were developed in recent years to resemble the situation *in vivo*.^[80, 81] One promising approach are models based on human induced pluripotent stem cells (hiPSCs) derived BBB endothelial cells.^[52, 82] Using such a hiPSC-derived model, physiological characteristics like high transendothelial electrical resistances (TEER)

up to $2,500 \Omega\text{-cm}^2$, distinct upregulation of typical BBB genes as well as the formation of an *in vivo*-like tight junction (TJ) network could be achieved.^[52] The hiPSC-derived BBB endothelial cells were seeded on top of a transwell insert and subsequently the permeability of ATV from the apical to the basolateral compartment was investigated (Figure 7a). A ratio of **A-pBuOzi-A/ATV** = 10/1 g/L was chosen due to the small size of the respective ATV-loaded micelles (Figure 1e,f) potentially facilitating transcellular permeability, assuming integrity of the drug loaded micelles. The latter is not necessarily given due to e.g. potential transfer of incorporated ATV to proteins^[83] present in solution as observed for **A-pBuOx-A/PTX** *in vitro* and *in vivo*.^[84] ATV was either solubilized with **A-pBuOzi-A** or dissolved in DMSO and applied at 90 μM (50 mg/L) as well as 150 μM (83 mg/L). For comparison, oral administration of 40 mg ATV in hypercholesterolaemic haemodialysis patients resulted in ATV peak plasma concentrations of $28.6 \pm 15.2 \mu\text{g/L}$ (51 nM; reached 1-2 hours after initial administration), together with the active metabolites o- and p-OH ATV (8.1 and 0.6 $\mu\text{g/L}$) as well as inactive 3-lactone metabolites (44.2 $\mu\text{g/L}$).^[85] This clearly shows the need of ATV-formulation to achieve necessary ATV concentrations potentially suitable for glioblastoma therapy. At both concentrations, no pronounced cytotoxic effects of ATV on the endothelial cells of the artificial BBB were observed after 4 h incubation, ensuring the integrity of the monolayer during the course of the experiment (Figure S10a). After 24 h incubation, again no cytotoxicity up to ATV = 90 μM occurred (Figure S10b). Only at ATV = 150 μM , cell viability decreased to 41 % and 49 % for DMSO/ATV and **A-pBuOzi-A/ATV**, respectively. ATV was quantified in the apical and basolateral chamber after 4 h and 24 h incubation. To ensure the permeability analysis of **A-pBuOzi-A/ATV** and DMSO/ATV through the BBB endothelial cell layer itself, transwells without cells were always included to correct the permeation values for the barrier formed by the membrane support. In all cases, a higher ATV concentration occurred on the basolateral side of the latter compared to wells containing cells (Figure S11). Furthermore, diffusion through the blank membrane was more or less the same for **A-pBuOzi-A/ATV** and DMSO/ATV therefore excluding variances due to different diffusion profiles. With respect to the wells without cells, the ATV transport through the BBB was less efficient at apical ATV feed of 150 μM , compared to 90 μM (Figure 7b). Nevertheless, absolute basolateral ATV concentrations increased from 4 h to 24 h incubation and from $[\text{ATV}_{\text{feed}}] = 90 \mu\text{M}$ to 150 μM in all samples (Figure S11). For both ATV concentrations and time-points, ATV permeability was slightly higher for **A-pBuOzi-A/ATV** than for DMSO/ATV, however, the differences were within the standard deviations (Figure 7b). This suggests that our nanoformulation does not alter the permeation profile of ATV through this BBB *in vitro* model significantly. Whether this is due to a rapid release of ATV from the micelles to e.g. proteins present in medium or e.g. the disintegration of the ATV-loaded micelles at the cell-membrane – not further improving endocytosis or transcellular delivery – remains to be elucidated. However, rapid disintegration of drug-loaded micelles within the blood stream is not necessarily detrimental regarding therapeutic efficacy, as evidenced by POx/PTX nanoformulations, which exhibit an excellent therapeutic efficacy *in vivo*.^[84] Interestingly, the proportional basolateral ATV concentration with respect to the wells without cells increased from 4 h to 24 h incubation for both, DMSO/ATV and **A-pBuOzi-A/ATV** (Figure 7b). Taking a closer look at the TEER values showed a decrease in resistance after 24 h at both ATV feed concentrations of 90 and 150 μM (Figure 7c,d). Even though we observed no ATV cytotoxicity up to 90 μM (Figure S10), the integrity of the BBB is apparently affected, probably

through a loosening of the tight junctions. This may be an early indication of cytotoxic effects. Although the transport across the BBB is not significantly improved, the presented novel POzi/ATV formulation may allow much higher ATV serum concentrations, compared to oral administration or alternative drug delivery systems, as much higher ATV concentrations can potentially be administered. Therefore, therapeutic doses may be reached, even without improved transport across the BBB.




Figure 7: a) Setup to investigate the permeability of ATV through hiPSC-derived *in vitro* models of the human blood-brain barrier (BBB) in a transwell setup (image adapted from Appelt-Menzel *et al.* [52]); b) A-pBuOzi-A/ATV = 10/1 [g/L] (blue) or DMSO/ATV (yellow) were diluted with cell specific medium to desired ATV concentrations of 90 µM or 150 µM and applied to the apical side of the transwells. Subsequently, basolateral ATV concentrations were quantified after 4 h and 24 h incubation with respect to the permeability through wells without cells (= control). Permeation was determined in three individual transwell-plates each containing the respective samples in duplicates. Data are presented as mean ± SD; n = 3; TEER values of non-treated BBB as well as treatment with c) DMSO/ATV or d) A-pBuOzi-A/ATV for either 4 h (solid bars) or 24 h (dashed bars). TEER values are presented with respect to TEER values measured prior to the transport assay (=control). TEER values were determined in three positions of three individual transwell-plates each containing the respective samples in duplicates. Data are presented as mean ± SEM (n = 3, *p<0.05, **p<0.01, ***p<0.001).

Furthermore, co-administration with agents temporarily permeabilizing the BBB could help to increase the ATV concentration across the BBB. Such agent could be SP1049C or small molecules known to permeabilize the BBB. Possibly, such agent could be coformulated with ATV and therefore improve co-delivery of both APIs.

CONCLUSION

We presented a novel nanoformulation of atorvastatin (ATV), a statin with potential in the treatment of various tumors, including glioblastoma. A moderate increase in the apparent aqueous solubility of ATV by a factor of 100 was achieved, but the sizes of the formed particles are too large for intravenous administration at the highest drug loading. Only at low drug loading < 10 wt.%, nanoformulations ($D_h < 50$ nm) were obtained while at higher loading, large submicron particles were formed. The encapsulated ATV was fully bioactive and exhibited IC_{50} values in the low to medium micromolar range in a panel of different glioblastoma cell

lines with no systematic difference between free, DMSO solubilized ATV and ATV solubilized using polymer micelles. In contrast, in tumor spheroids prepared from CT-2A mouse glioma and bRITS-G2 mouse glioma cancer stem cells, the micellar formulation was consistently more active. Very interestingly, we found particularly high activity against bRITS-G2 with minimal cell survival even at low micromolar ATV concentrations. Finally, transport through a blood-brain-barrier *in vitro* model based on differentiated human induced pluripotent stem cells was tested and revealed similar transport of micellar ATV and ATV dissolved by DMSO. However, as our novel micellar ATV formulations may enable much higher serum concentration of ATV, therapeutic doses may still be possible. Especially by combination with other active agents, micellar ATV may have potential for the treatment of glioblastoma.

ACKNOWLEDGEMENT

This work was supported by the Free State of Bavaria and the Deutsche Forschungsgemeinschaft (Project number 398461692, awarded to R.L.). Moreover, M.M.L. would like to thank the Evonik Foundation for providing a doctoral fellowship. We thank Christian May for technical support. Furthermore, we thank Dr. Tapia-Perez for inspiring this study.

REFERENCES

- [1] P. D. Delgado-López, E. M. Corrales-García, *Clin. Transl. Oncol.* **2016**, *18*, 1062-1071.
- [2] Q. T. Ostrom, H. Gittleman, P. Liao, C. Rouse, Y. Chen, J. Dowling, Y. Wolinsky, C. Kruchko, J. Barnholtz-Sloan, *Neuro-Oncol.* **2014**, *16 Suppl 4*, iv1-iv63.
- [3] R. Stupp, M. E. Hegi, W. P. Mason, M. J. van den Bent, M. J. B. Taphoorn, R. C. Janzer, S. K. Ludwin, A. Allgeier, B. Fisher, K. Belanger, P. Hau, A. A. Brandes, J. Gijtenbeek, C. Marosi, C. J. Vecht, K. Mokhtari, P. Wesseling, S. Villa, E. Eisenhauer, T. Gorlia, M. Weller, D. Lacombe, J. G. Cairncross, R.-O. Mirimanoff, *Lancet Oncol.* **2009**, *10*, 459-466.
- [4] Q. Xie, S. Mittal, M. E. Berens, *Neuro-Oncol.* **2014**, *16*, 1575-1584.
- [5] S. Osuka, E. G. Van Meir, *J. Clin. Investig.* **2017**, *127*, 415-426.
- [6] C. P. Haar, P. Hebbbar, G. C. Wallace, A. Das, W. A. Vandergrift, J. A. Smith, P. Giglio, S. J. Patel, S. K. Ray, N. L. Banik, *Neurochem. Res.* **2012**, *37*, 1192-1200.
- [7] W. M. Pardridge, *J. Cereb. Blood Flow Metab.* **2012**, *32*, 1959-1972.
- [8] P. K. Pandey, A. K. Sharma, U. Gupta, *Tissue barriers* **2015**, *4*, e1129476-e1129476.
- [9] S. Y. Lee, *Genes & diseases* **2016**, *3*, 198-210.
- [10] M. Farnier, J. Davignon, *Am. J. Cardiol.* **1998**, *82*, 3J-10J.
- [11] J. K. Liao, *Am. J. Cardiol.* **2005**, *96*, 24F-33F.
- [12] K. Hindler, C. S. Cleeland, E. Rivera, C. D. Collard, *The Oncologist* **2006**, *11*, 306-315.
- [13] Y. G. Shellman, D. Ribble, L. Miller, J. Gendall, K. VanBuskirk, D. Kelly, D. A. Norris, R. P. Dellavalle, *Melanoma Res.* **2005**, *15*, 83-89.
- [14] M. Koyuturk, M. Ersoz, N. Altioek, *Neurosci. Lett.* **2004**, *370*, 212-217.
- [15] R. Girgert, Y. Vogt, D. Becke, G. Bruchelt, P. Schweizer, *Cancer Lett.* **1999**, *137*, 167-172.

- [16] A. Sassano, E. Katsoulidis, G. Antico, J. K. Altman, A. J. Redig, S. Minucci, M. S. Tallman, L. C. Plataniias, *Cancer Res.* **2007**, *67*, 4524.
- [17] M. Yanae, M. Tsubaki, T. Satou, T. Itoh, M. Imano, Y. Yamazoe, S. Nishida, *J. Exp. Clin. Canc. Res.* **2011**, *30*, 74.
- [18] S. Pisanti, P. Picardi, E. Ciaglia, A. D'Alessandro, M. Bifulco, *Pharmacol. Res.* **2014**, *88*, 84-98.
- [19] S. Gizzo, M. Quaranta, G. B. Nardelli, M. Noventa, *Curr. Drug Targets* **2015**, *16*, 1142-1159.
- [20] P. Prasanna, A. Thibault, L. Liu, D. Samid, *J. Neurochem.* **1996**, *66*, 710-716.
- [21] P. Jiang, R. Mukthavaram, Y. Chao, N. Nomura, I. S. Bharati, V. Fogal, S. Pastorino, D. Teng, X. Cong, S. C. Pingle, S. Kapoor, K. Shetty, A. Aggrawal, S. Vali, T. Abbasi, S. Chien, S. Kesari, *Br. J. Cancer* **2014**, *111*, 1562.
- [22] N. Bayat, S. Ebrahimi-Barough, A. Norouzi-Javidan, H. Saberi, R. Tajerian, M. M. M. Ardakan, S. Shirian, A. Ai, J. Ai, *Biomed. Pharmacother.* **2016**, *84*, 1959-1966.
- [23] Y. Yongjun, H. Shuyun, C. Lei, C. Xiangrong, Y. Zhilin, K. Yiquan, *J. Neuroimmunol.* **2013**, *260*, 1-8.
- [24] N. Bayat, S. Ebrahimi-Barough, A. Norouzi-Javidan, H. Saberi, M. M. M. Ardakan, A. Ai, M. Soleimannejad, J. Ai, *Mol. Neurobiol.* **2018**, *55*, 2102-2110.
- [25] F. Colotta, P. Allavena, A. Sica, C. Garlanda, A. Mantovani, *Carcinogenesis* **2009**, *30*, 1073-1081.
- [26] Y. T. Yeung, K. L. McDonald, T. Grewal, L. Munoz, *Br. J. Pharmacol.* **2013**, *168*, 591-606.
- [27] K. Shimada, R. Skouta, A. Kaplan, W. S. Yang, M. Hayano, S. J. Dixon, L. M. Brown, C. A. Valenzuela, A. J. Wolpaw, B. R. Stockwell, *Nat. Chem. Biol.* **2016**, *12*, 497.
- [28] A. K. Altwaigi, W. Alghareeb, F. Alnajjar, E. Alsaeed, A. Balbaid, H. Alhussain, S. Aldanan, Y. Orz, A. Lari, A. Alsharm, *Ann. Oncol.* **2016**, *27*.
- [29] T.-T. Tang, Y. Song, Y.-J. Ding, Y.-H. Liao, X. Yu, R. Du, H. Xiao, J. Yuan, Z.-H. Zhou, M.-Y. Liao, R. Yao, H. Jevallee, G.-P. Shi, X. Cheng, *J. Lipid Res.* **2011**, *52*, 1023-1032.
- [30] W. A. Banks, *BMC Neurol.* **2009**, *9 Suppl 1*, S3-S3.
- [31] J. B. David, *Curr. Pharm. Des.* **2004**, *10*, 1295-1312.
- [32] I. Tamai, A. Tsuji, *J. Pharm. Sci.* **2000**, *89*, 1371-1388.
- [33] A. Tsuji, A. Saheki, I. Tamai, T. Terasaki, *J. Pharmacol. Exp. Ther.* **1993**, *267*, 1085.
- [34] A. Saheki, T. Terasaki, I. Tamai, A. Tsuji, *Pharm. Res.* **1994**, *11*, 305-311.
- [35] B. G. Schultz, D. K. Patten, D. J. Berlau, *Transl. Neurodegener.* **2018**, *7*, 5-5.
- [36] F. M. Sahebzamani, C. L. Munro, O. C. Marroquin, D. M. Diamond, E. Keller, K. E. Kip, *J. Pharmacovigil.* **2014**, *2*, 1000141-1100015.
- [37] J. Shi, P. W. Kantoff, R. Wooster, O. C. Farokhzad, *Nat. Rev. Cancer* **2017**, *17*, 20-37.
- [38] H. Cabral, K. Miyata, K. Osada, K. Kataoka, *Chem. Rev.* **2018**, *118*, 6844-6892.
- [39] H. Danafar, K. Rostamizadeh, M. Hamidi, *J. Pharm. Investig.* **2017**, *48*, 381-391.
- [40] S. Andalib, P. Molhemazar, H. Danafar, *J. Biomater. Appl.* **2017**, *32*, 1127-1138.
- [41] P. Xu, H. Yu, Z. Zhang, Q. Meng, H. Sun, X. Chen, Q. Yin, Y. Li, *Biomaterials* **2014**, *35*, 7574-7587.
- [42] G. M. Mekhail, A. O. Kamel, G. A. S. Awad, N. D. Mortada, *Int. J. Biol. Macromol.* **2012**, *51*, 351-363.
- [43] S. S. A. C. H. G. P. D. C. R. B. A. Ravindran, *PLoS One* **2014**, *9*, e86317.
- [44] S. Şimşek, H. Eroğlu, B. Kurum, K. Ulubayram, *J. Microencapsul.* **2013**, *30*, 10-20.
- [45] E. V. Batrakova, S. Li, D. W. Miller, A. V. Kabanov, *Pharm. Res.* **1999**, *16*, 1366-1372.
- [46] T. O. Price, S. A. Farr, X. Yi, S. Vinogradov, E. V. Batrakova, W. A. Banks, A. V. Kabanov, *J. Pharmacol. Exp. Ther.* **2010**, jpet.109.158147.
- [47] J. Tong, X. Yi, R. Luxenhofer, W. A. Banks, R. Jordan, M. C. Zimmerman, A. V. Kabanov, *Mol. Pharm.* **2013**, *10*, 360-377.
- [48] W. A. Banks, A. Gertler, G. Solomon, L. Niv-Spector, M. Shpilman, X. Yi, E. Batrakova, S. Vinogradov, A. V. Kabanov, *Physiol. Behav.* **2011**, *105*, 145-149.
- [49] H. Witte, W. Seeliger, *Liebigs Ann. Chem.* **1974**, *1974*, 996-1009.
- [50] M. M. Lübtow, M. S. Haider, M. Kirsch, S. Klisch, R. Luxenhofer, *Biomacromolecules* **2019**, *20*, 3041-3056.
- [51] R. Luxenhofer, A. Schulz, C. Roques, S. Li, T. K. Bronich, E. V. Batrakova, R. Jordan, A. V. Kabanov, *Biomaterials* **2010**, *31*, 4972-4979.
- [52] A. Appelt-Menzel, A. Cubukova, K. Günther, F. Edenhofer, J. Piontek, G. Krause, T. Stüber, H. Walles, W. Neuhaus, M. Metzger, *Stem Cell Rep.* **2017**, *8*, 894-906.
- [53] M. M. Lübtow, L. Hahn, M. S. Haider, R. Luxenhofer, *J. Am. Chem. Soc.* **2017**, *139*, 10980-10983.
- [54] L. Hahn, M. M. Lübtow, T. Lorson, F. Schmitt, A. Appelt-Menzel, R. Schobert, R. Luxenhofer, *Biomacromolecules* **2018**, *19*, 3119-3128.
- [55] M. M. Lübtow, L. Keßler, A. Appelt-Menzel, T. Lorson, N. Gangloff, M. Kirsch, S. Dahms, R. Luxenhofer, *Macromol. Biosci.* **2018**, *18*, 1800155.
- [56] Y. Seo, A. Schulz, Y. Han, Z. He, H. Bludau, X. Wan, J. Tong, T. K. Bronich, M. Sokolsky, R. Luxenhofer, R. Jordan, A. V. Kabanov, *Polym. Adv. Technol.* **2015**, *26*, 837-850.
- [57] M. S. Haider, J. Schreiner, S. Kendl, M. Kroiß, R. Luxenhofer, *Macromol. Biosci.* **2019**, doi: 10.1002/mabi.201900178.
- [58] M. M. Lübtow, H. Marciniak, A. Schmiedel, M. Roos, C. Lambert, R. Luxenhofer, *Chem.: Eur. J.* **2019**, *25*, 12601-12610.
- [59] A.-C. Pöppler, M. M. Lübtow, J. Schlauersbach, J. Wiest, L. Meinel, R. Luxenhofer, *Angew. Chem. Int. Ed.* **2019**, doi:10.1002/anie.201908914.
- [60] S. Danson, D. Ferry, V. Alakhov, J. Margison, D. Kerr, D. Jowle, M. Brampton, G. Halbert, M. Ranson, *Br. J. Cancer* **2004**, *90*, 2085-2091.
- [61] A. V. Kabanov, E. V. Batrakova, D. W. Miller, *Adv. Drug Deliv. Rev.* **2003**, *55*, 151-164.
- [62] A. V. Kabanov, E. V. Batrakova, V. Y. Alakhov, *J. Control. Release* **2002**, *82*, 189-212.
- [63] M. M. Lübtow, L. C. Nelke, J. Seifert, J. Kühnemundt, G. Sahay, G. Dandekar, S. L. Nietzer, R. Luxenhofer, *J. Control. Release* **2019**, *303*, 162-180.
- [64] J. Crosbie, M. Magnussen, R. Dornbier, A. Iannone, T. A. Steele, *Biomark. Res.* **2013**, *1*, 33-33.
- [65] G. Y. Di Veroli, C. Fornari, I. Goldlust, G. Mills, S. B. Koh, J. L. Bramhall, F. M. Richards, D. I. Jodrell, *Sci. Rep.* **2015**, *5*, 14701.
- [66] E. J. Calabrese, *Environ. Pollut.* **2013**, *182*, 452-460.
- [67] P. Peng, W. Wei, C. Long, J. Li, *Biochem. Biophys. Res. Commun.* **2017**, *489*, 293-298.

- [68] J. H. Tapia-Pérez, E. Kirches, C. Mawrin, R. Firsching, T. Schneider, *Cancer Chemother. Pharmacol.* **2011**, *67*, 1193-1201.
- [69] S. K. Carlsson, S. P. Brothers, C. Wahlestedt, *EMBO Mol. Med.* **2014**, *6*, 1359-1370.
- [70] J. T. Huse, E. C. Holland, *Nat. Rev. Cancer* **2010**, *10*, 319.
- [71] E. Di Tomaso, J. C. S. Pang, H. K. Ng, P. Y. P. Lam, X. X. Tian, K. W. Suen, A. B. Y. Hui, N. M. Hjelm, *Neuropathol. Appl. Neurobiol.* **2000**, *26*, 22-30.
- [72] M. Schulze, O. Fedorchenko, T. G. Zink, C. B. Knobbe-Thomsen, S. Kraus, S. Schwinn, A. Beilhack, G. Reifenberger, C. M. Monoranu, A. L. Sirén, E. Jeanclos, A. Gohla, *Oncogene* **2015**, *35*, 3163.
- [73] R.-Z. Lin, H.-Y. Chang, *Biotechnol. J.* **2008**, *3*, 1172-1184.
- [74] B. Desoize, J.-C. Jardillier, *Crit. Rev. Oncol. Hematol.* **2000**, *36*, 193-207.
- [75] J. E. Visvader, G. J. Lindeman, *Nat. Rev. Cancer* **2008**, *8*, 755.
- [76] J. D. Lathia, S. C. Mack, E. E. Mulkearns-Hubert, C. L. L. Valentim, J. N. Rich, *Genes Dev.* **2015**, *29*, 1203-1217.
- [77] J. N. Rich, *Cancer Res.* **2007**, *67*, 8980.
- [78] D. Beier, J. B. Schulz, C. P. Beier, *Mol. Cancer* **2011**, *10*, 128.
- [79] F. Zhang, C.-L. Xu, C.-M. Liu, *Drug Des. Dev. Ther.* **2015**, *9*, 2089-2100.
- [80] A. Wolff, M. Antfolk, B. Brodin, M. Tenje, *J. Pharm. Sci.* **2015**, *104*, 2727-2746.
- [81] A. Avdeef, M. A. Deli, W. Neuhaus, in *Blood-Brain Barrier in Drug Discovery*, John Wiley, **2015**, pp. 188-237.
- [82] E. S. Lippmann, S. M. Azarin, J. E. Kay, R. A. Nessler, H. K. Wilson, A. Al-Ahmad, S. P. Palecek, E. V. Shusta, *Nat. Biotechnol.* **2012**, *30*, 783.
- [83] Q. Wang, C.-r. Huang, M. Jiang, Y.-y. Zhu, J. Wang, J. Chen, J.-h. Shi, *Spectrochim. Acta A* **2016**, *156*, 155-163.
- [84] Z. He, X. Wan, A. Schulz, H. Bludau, M. A. Dobrovolskaia, S. T. Stern, S. A. Montgomery, H. Yuan, Z. Li, D. Alakhova, M. Sokolsky, D. B. Darr, C. M. Perou, R. Jordan, R. Luxenhofer, A. V. Kabanov, *Biomaterials* **2016**, *101*, 296-309.
- [85] R. L. Lins, K. E. Matthys, G. A. Verpooten, P. C. Peeters, M. Dratwa, J. C. Stolear, N. H. Lameire, *Nephrol. Dial. Transplant.* **2003**, *18*, 967-976.
-